19 studies found for:    alectinib
Show Display Options
Rank Status Study
1 Recruiting The Study of Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Condition: Hepatic Impairment
Intervention: Drug: Alectinib
2 Recruiting Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Alectinib;   Drug: Bevacizumab
3 Recruiting A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Crizotinib
4 Active, not recruiting ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Crizotinib
5 Completed Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Alectinib
6 Completed
Has Results
A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
Condition: Healthy Volunteer
Interventions: Drug: Alectinib;   Drug: Posaconazole
7 Completed
Has Results
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
Condition: Healthy Volunteer
Interventions: Drug: Alectinib;   Drug: Esomeprazole;   Other: High Fat and Calorie Meal;   Other: Standard Meal
8 Recruiting Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Docetaxel;   Drug: Pemetrexed
9 Recruiting A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Atezolizumab;   Drug: Erlotinib
10 Active, not recruiting
Has Results
A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: RO5424802
11 Completed A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802
Condition: Healthy Volunteer
Intervention: Drug: RO5424802
12 Completed
Has Results
A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802
Condition: Healthy Volunteer
Interventions: Drug: RO5424802;   Drug: rifampin
13 Completed
Has Results
A Study Examining the Bioequivalence of 3 Alectinib (RO5424802) Test Formulations to a Reference Formulation of in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: Part 1 (Fasted): Treatment A;   Drug: Part 1 (Fasted): Treatment B;   Drug: Part 1 (Fasted): Treatment C;   Drug: Part 1 (Fasted): Treatment D;   Drug: Part 2 (Fed): Treatment A;   Drug: Part 2 (Fed): Treatment B;   Drug: Part 2 (Fed): Treatment C;   Drug: Part 2 (Fed): Treatment D
14 Unknown  A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer
Condition: ALK-Rearranged Non-Small Cell Lung Cancer
Intervention: Drug: CH5424802
15 Active, not recruiting
Has Results
A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: RO5452802
16 Recruiting LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: LDK378
17 Not yet recruiting Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib;   Drug: Alectinib;   Drug: Trastuzumab emtansine
18 Not yet recruiting Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: brigatinib
19 Completed Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Condition: Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Intervention: Drug: LDK378

Study has passed its completion date and status has not been verified in more than two years.